Announced
Completed
XOMA completed the acquisition of Kinnate Biopharma for $122m.
Synopsis
XOMA, a biotechnology royalty aggregator, completed the acquisition of Kinnate Biopharma, a clinical-stage precision oncology company, for $122m. Kinnate Biopharma is a clinical-stage precision oncology company founded with a mission to inspire hope in those battling cancer by expanding on the promise of targeted therapies.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Seller Team (12)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite